Trial Profile
A Phase 2, Dose-Ranging Study of the Safety and Efficacy of ADX415 Immediate-Release in the Treatment of Essential Hypertension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Dec 2008
Price :
$35
*
At a glance
- Drugs ADX 415 (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- 16 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Nov 2008 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 23 Oct 2008 Investigational New Drug Application approved by US Food and Drug Administration according to an Addrenex Pharmaceuticals media release.